Literature DB >> 8470834

Assessing the diagnostic value of an ECG containing leads V4R, V8, and V9: the 15-lead ECG.

R J Zalenski1, D Cooke, R Rydman, E P Sloan, D G Murphy.   

Abstract

STUDY
OBJECTIVES: To assess sensitivity, specificity, and odds ratios of ECG findings on leads V4R, V8, and V9 for acute myocardial infarction.
DESIGN: Prospective, two-stage cohort study.
SETTING: A 660-bed university-affiliated community hospital. TYPE OF PARTICIPANTS: One hundred forty-nine admitted patients with suspected myocardial infarction or unstable angina.
INTERVENTIONS: Standard 12-lead ECG followed immediately by V4R, V8, and V9. MEASUREMENTS: Initial ECG findings of ST-segment displacement, Q waves, T-wave inversion, and eligibility for thrombolytic therapy.
RESULTS: Major abnormalities (ST-segment deviation, T-wave inversion, Q waves) were found on the extra three leads in 28.9% (43 of 149) of patients. Sensitivity of ST-segment elevation for acute myocardial infarction on 12 versus 15 leads increased from 47.1% to 58.8%, respectively, with no decrease in specificity. McNemar's pair-matched analysis for ST-segment elevation on myocardial infarction subgroup showed an association of ST elevation with the 15-lead ECG (P < .05). An eightfold increase in the odds of detecting ST elevation was found (90% confidence interval, 1.42 to 14.58); 22% of patients negative for ST elevation on 12 leads were positive on 15 leads. Analysis of ECG criteria for thrombolytic therapy presenting uniquely on extra leads showed an increased sensitivity from 35.3% to 44.1% on 12 versus 15 leads, respectively; there was a sixfold increase in the odds of meeting ECG thrombolytic therapy criteria (90% confidence interval, 0.34 to 11.66); 13.5% of patients not meeting criteria on 12 leads did so on 15 leads.
CONCLUSION: The 15-lead ECG provides increased sensitivity and odds of detecting ST-segment elevation in acute myocardial infarction patients with no loss of specificity; its use may expand the selection of thrombolytic therapy candidates and provide a fuller ECG description of the extent of myocardial injury and necrosis.

Entities:  

Mesh:

Year:  1993        PMID: 8470834     DOI: 10.1016/s0196-0644(05)80792-9

Source DB:  PubMed          Journal:  Ann Emerg Med        ISSN: 0196-0644            Impact factor:   5.721


  8 in total

1.  The electrocardiographic differential diagnosis of ST segment depression.

Authors:  T Pollehn; W J Brady; A D Perron; F Morris
Journal:  Emerg Med J       Date:  2002-03       Impact factor: 2.740

2.  Chest pain in a patient with a tall R wave in V1.

Authors:  Kenneth McManus; Gregory Condos; Andrew Lin
Journal:  BMJ Case Rep       Date:  2014-08-22

3.  Use of indicative and reciprocal electrocardiographic changes to help localize the site of coronary occlusion.

Authors:  D L Glancy; W Doghmi
Journal:  Proc (Bayl Univ Med Cent)       Date:  2001-01

Review 4.  Emergency department and office-based evaluation of patients with chest pain.

Authors:  Michael C Kontos; Deborah B Diercks; J Douglas Kirk
Journal:  Mayo Clin Proc       Date:  2010-03       Impact factor: 7.616

5.  Posterior myocardial infarction: the dark side of the moon.

Authors:  E O F van Gorselen; F W A Verheugt; B T J Meursing; A J M Oude Ophuis
Journal:  Neth Heart J       Date:  2007-01       Impact factor: 2.380

6.  ECG Diagnosis: Isolated Posterior Wall Myocardial Infarction.

Authors:  Joel T Levis
Journal:  Perm J       Date:  2015

7.  The Importance of the 15-lead Versus 12-lead ECG Recordings in the Diagnosis and Treatment of Right Ventricle and Left Ventricle Posterior and Lateral Wall Acute Myocardial Infarctions.

Authors:  Ioannis Vogiatzis; Efstathios Koulouris; Antonios Ioannidis; Evangelos Sdogkos; Maria Pliatsika; Pavlos Roditis; Markos Goumenakis
Journal:  Acta Inform Med       Date:  2019-03

Review 8.  [Detection of ECG alterations typical for myocardial ischemia : New methods 2021].

Authors:  Sascha Beck; Valeria Martínez Pereyra; Andreas Seitz; Raffi Bekeredjian; Udo Sechtem; Peter Ong
Journal:  Internist (Berl)       Date:  2021-05-26       Impact factor: 0.743

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.